These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 7944532

  • 21. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
    Shalitin S, Carmi D, Weintrob N, Phillip M, Miskin H, Kornreich L, Zilber R, Yaniv I, Tamary H.
    Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
    [Abstract] [Full Text] [Related]

  • 22. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
    Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V.
    Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219
    [Abstract] [Full Text] [Related]

  • 23. Multicentre study on prevalence of endocrine complications in thalassaemia major. Italian Working Group on Endocrine Complications in Non-endocrine Diseases.
    Clin Endocrinol (Oxf); 1995 Jun; 42(6):581-6. PubMed ID: 7634497
    [Abstract] [Full Text] [Related]

  • 24. [Growth and endocrine function in major thalassemia].
    Pérignon F, Brauner R, Souberbielle JC, de Montalembert M, Girot R.
    Arch Fr Pediatr; 1993 Oct; 50(8):657-63. PubMed ID: 8002739
    [Abstract] [Full Text] [Related]

  • 25. Correlation of hepcidin level with insulin resistance and endocrine glands function in major thalassemia.
    Al-Hakeim HK, Al-Khakani MM, Al-Kindi MA.
    Adv Clin Exp Med; 2015 Oct; 24(1):69-78. PubMed ID: 25923089
    [Abstract] [Full Text] [Related]

  • 26. [Program of hypertransfusion and chelation with desferrioxamine in 10 patients with thalassemia major].
    Albo C, Cabrera J, Dios A, Castro M, Ares C, Constenla I, López D.
    Sangre (Barc); 1995 Dec; 40(6):441-5. PubMed ID: 8850225
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Thyroid dysfunction in multi-transfused iron loaded thalassemia patients.
    Agarwal MB, Shah S, Vishwanathan C, Rajadhyaksha G, Bhave AA, Dube SR, Billa V, Malkan G, Bajan K.
    Indian Pediatr; 1992 Aug; 29(8):997-102. PubMed ID: 1459722
    [Abstract] [Full Text] [Related]

  • 30. Growth and puberty in thalassemia major.
    Raiola G, Galati MC, De Sanctis V, Caruso Nicoletti M, Pintor C, De Simone M, Arcuri VM, Anastasi S.
    J Pediatr Endocrinol Metab; 2003 Mar; 16 Suppl 2():259-66. PubMed ID: 12729401
    [Abstract] [Full Text] [Related]

  • 31. The combined pituitary function test in children: an evaluation of the clinical usefulness of TRH and LHRH stimulation tests through a retrospective analysis of one hundred and twenty six cases.
    Westwood ME, Butler GE, McLellan AC, Barth JH.
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):727-33. PubMed ID: 10848877
    [Abstract] [Full Text] [Related]

  • 32. [Osteopenia in beta-thalassemia major].
    Brändle M, Galeazzi RL, Morant R, Oesterle M.
    Schweiz Med Wochenschr; 1996 Nov 02; 126(44):1867-74. PubMed ID: 8984599
    [Abstract] [Full Text] [Related]

  • 33. Hypogonadotropic hypogonadism in severe beta-thalassemia: effect of chelation and pulsatile gonadotropin-releasing hormone therapy.
    Wang C, Tso SC, Todd D.
    J Clin Endocrinol Metab; 1989 Mar 02; 68(3):511-6. PubMed ID: 2493034
    [Abstract] [Full Text] [Related]

  • 34. Pharmacokinetics of deferiprone in patients with β-thalassaemia: impact of splenectomy and iron status.
    Limenta LM, Jirasomprasert T, Jittangprasert P, Wilairat P, Yamanont P, Chantharaksri U, Fucharoen S, Morales NP.
    Clin Pharmacokinet; 2011 Jan 02; 50(1):41-50. PubMed ID: 21028920
    [Abstract] [Full Text] [Related]

  • 35. The impact of genotype on endocrine complications in thalassaemia major.
    Skordis N, Michaelidou M, Savva SC, Ioannou Y, Rousounides A, Kleanthous M, Skordos G, Christou S.
    Eur J Haematol; 2006 Aug 02; 77(2):150-6. PubMed ID: 16800840
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Early onset of endocrine abnormalities in beta-thalassemia major in a developing country.
    Gulati R, Bhatia V, Agarwal SS.
    J Pediatr Endocrinol Metab; 2000 Jun 02; 13(6):651-6. PubMed ID: 10905390
    [Abstract] [Full Text] [Related]

  • 38. Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major.
    Casale M, Citarella S, Filosa A, De Michele E, Palmieri F, Ragozzino A, Amendola G, Pugliese U, Tartaglione I, Della Rocca F, Cinque P, Nobili B, Perrotta S.
    Am J Hematol; 2014 Dec 02; 89(12):1102-6. PubMed ID: 25197009
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.